Efficiency Control of Fluticasone/Formoterol K-haler (Medium Strength) vs ICS/LABA (High Strength) in Asthma Patients
Study Details
Study Description
Brief Summary
Clinical trial to demonstrate whether, in patients with moderate asthma, to treat with IC / LABA a medium dose, but not controlled, to achieve a similar degree of control by making a progressive increase of that treatment (CI / LABA a high dose) versus switching to fluticasone / Formoterol K-Haler at medium dose, under conditions of usual clinical practice.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Asthma is a common chronic respiratory disease that affects about 300 million people worldwide. Although knowledge about asthma and its treatment has improved over the past decade, morbidity and mortality remain considerable.
Inhaled therapy is the treatment of choice in persistent asthma. Lower doses of drug are used that maximize the therapeutic effect and minimize side effects.
Inhaled therapy is administered primarily through inhalers. The goal is to deliver the maximum amount of medication to your therapeutic target in the lungs → lung deposit Each inhaler offers a different lung deposit figure (data in ideal conditions). However, asthma control also depends on other factors (inhalation technique, adhesion, asthma severity, drug dose, etc.).
The K-haler® inhaler device has obtained a high lung deposit (≈45% of the emitted dose) and an easy-to-use device.
In general, the rest of the CI / LABA inhalers offer lower deposit figures. They are between ≈10-40% of the dose.
Taking into account all that has been said in the introduction section, it has been decided to design this low-intervention clinical trial, to verify whether, those technical benefits of K-haler®, control asthma in a similar way using lower doses of IC .
If these hypotheses were confirmed, it would allow for an effective therapeutic option in the control of asthma using a lower therapeutic dose, saving IC and a lower probability of producing side effects.
Demonstrate whether, in patients with moderate asthma, to treat with IC / LABA a medium dose, but not controlled, to achieve a similar degree of control by making a progressive increase of that treatment (CI / LABA a high dose) versus switching to fluticasone / Formoterol K-Haler at medium dose, under conditions of usual clinical practice.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Fluticasone/formoterol k-haler (medium strength) In this arm, uncontrolled patients who arrive at the consultation with their fixed combination of ICs (Inhaled CorticosteroidS) / LABA (Long-Acting Beta2-Agonist) (medium strength) will change their treatment to Fluticasone / formoterol k-haler (medium strength) |
Combination Product: fluticasone/formoterol k-haler (medium strength)
2 inhalations every 12 hours
Other Names:
|
| Active Comparator: Standard of Care (SoC) In this arm, uncontrolled patients arriving at the consultation with their fixed combination of ICs / LABA (medium strength) will change their treatment to the same fixed combination of ICs / LABA (high strength) |
Combination Product: Standard of care (ICs/LABA high strength)
Depend of the ICs/LABA combination
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Control of asthma [24 weeks]
The control of asthma in patients with persistent asthma will be measured by scoring the ACQ-7 questionnaire (Asthma Control Questionnaire): Well controlled: ≤ 0.75, Partially controlled: from 0.75 to 1.50, Poorly controlled:> 1.50
Secondary Outcome Measures
- Degree of asthma control according to GINA (Global Initiative for Asthma) questionnaire of four questions [24 weeks]
Well Controlled (negative answer in the 4 questions), Partially controlled (affirmative answer in 1 or 2 of the answers), Uncontrolled (affirmative answer in 3 or 4 of the answers)
- Success in asthma treatment [24 weeks]
Defined as asthma patients who progress from poorly controlled asthma to partially or well controlled asthma, or from partially controlled asthma to controlled asthma, with no change in baseline asthma treatment after randomization Measured by scoring the ACQ-7 questionnaire: Well controlled: ≤ 0.75, Partially controlled: from 0.75 to 1.50, Poorly controlled:> 1.50
- Adherence to treatment [24 weeks]
Through TAI-12 questionnaire (Erratic Total Score 1-5 items, Deliberate Total Score 6-10 items, Unconscious Total Score 11-12 items) And through electronic prescription (if the amount of medication withdrawn in pharmacy matches that prescribed by the doctor)
- Critical errors with the inhaler [24 weeks]
Number of critical errors
- Patient satisfaction with the inhaler [24 weeks]
Through the FSI-10 (Feeling of Satisfaction with Inhaler) questionnaire (It consists of 10 questions, each with 5 response options on a 5-step Likert scale ("a lot", "a lot", "something", "little" and "very little") scored, respectively, from 5 to 1 (score total: 50). It evaluates the degree of patient satisfaction with the inhalation device and includes items related to comfort, difficulty, transportability and use.)
- Quality of Life of the patient [24 weeks]
Through Mini-AQLQ (Mini Asthma Quality of Life Questionnaire) questionnaire: This 15-item questionnaire is a short version of the complete 32-item questionnaire, but constitutes of the same 4 domains: symptoms, environment, emotions, activities, and covering a 2 week period. Scores range from 0-6 (lower is worse). The mini-AQLQ score is calculated as the average of domain items. The minimum clinically important difference is 0.5. This version has been developed to meet the needs of long-term monitoring, where efficiency may take precedent over precision of measurement
- Severe asthmatic exacerbations [24 weeks]
Number severe asthmatic exacerbations (require the use of systemic corticosteroids - oral, suspension or injection - or the increase in the dose of maintenance therapy for at least 3 days, or hospitalization or visits to the emergency room due to asthma that requires the use of systemic corticosteroids)
- Forced Expiratory Volume at first second (FEV1) [24 weeks]
Using the FEV1 score of the patient's spirometry
- Forced Vital Capacity (FVC) [24 weeks]
Using the FVC score of the patient's spirometry
- FEV1 / FVC ratio [24 weeks]
Using the FEV1 and FVC score of the patient's spirometry
- Safety of the drug in investigation. [24 weeks]
Type and incidence of adverse reactions
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age > or = 18 years.
-
Objective diagnosis of asthma (according to GEMA 4.4) (Guía Española de Manejo del Asma)
-
Patients in treatment with a stable average dose of IC in a fixed dose combination of IC / LABA *, without changes in the dose or in the inhaler, during the 3 months prior to inclusion, in accordance with its approved indication and Data sheet. * Except for K-Haler®
-
Patients who need, according to medical criteria, a dose increase of IC in the current fixed IC / LABA combination.
-
Inhalation technique: no critical errors with the current inhaler after training.
-
Patient with uncontrolled asthma with an ACQ> 0.75 points (partially controlled or poorly controlled asthma).
-
Informed consent in signed writing.
Exclusion Criteria:
-
Diagnosis of other respiratory pathology other than asthma (clinically relevant bronchiectasis, pulmonary fibrosis, COPD (Chronic Obstructive Pulmonary Disease) and others at the discretion of the investigator).
-
≥1 severe exacerbation (require the use of systemic corticosteroids - oral, suspension or injection - or increasing the dose of maintenance therapy for at least 3 days, or hospitalization or emergency room visits due to asthma requiring the use of systemic corticosteroids) in the last month or ≥3 in the previous 12 months.
-
Pregnancy or probability of being pregnant during the study.
-
Patient who, at the discretion of the investigator, does not have the capacity to complete the questionnaires.
-
Patient under treatment with monoclonal antibodies during the study.
-
Patient in another clinical trial.
-
Patient who has received an experimental drug in the last 30 days (12 weeks if it is a systemic steroid).
-
Do not use a MART (MAintenance and Reliever Therapy) strategy within 3 months prior to inclusion or during the trial
-
Patient in IC / LABA treatment according to MART strategy (Maintenance and Rescue).
-
Any contraindication expressed in the CI / LABA data sheet used.
-
Patient with poor adherence (TAI-10 ≤ 45)
-
Patients using an inhalation chamber
-
Patients with an index of Packages / year> 10
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Mundipharma Pharmaceuticals S.L.
- Alpha Bioresearch S.L.
- Dynamic Solutions
Investigators
- Study Director: José Luis Velasco Garrido, MD, Hospital Virgen de la Victoria
- Study Director: Javier Domínguez Ortega, MD, Hospital La Paz
- Principal Investigator: Patricia García Sidro, MD, Hospital La plana
- Principal Investigator: Ernesto Enrique Miranda, MD, Hospital General de Castellón
- Principal Investigator: Ana Gómez-Bastero Fernández, MD, Hospital Universitario Virgen Macarena
- Principal Investigator: Alicia Padilla Galo, MD, Hospital Costa del Sol
- Principal Investigator: Fernando Florido López, MD, Hospital San Cecilio
- Principal Investigator: Joaquín Quiralte Enriquez, MD, Hospital Virgen del Rocío
- Principal Investigator: Antolín López Viña, MD, Hospital Puerta de Hierro
- Principal Investigator: Carlos Almonacid Sánchez, MD, Hospital Universitario Ramon y Cajal
- Principal Investigator: María del Mar Gandolfo Cano, MD, Hospital de Fuenlabrada
- Principal Investigator: Paula López González, MD, Hospital Infanta Leonor
- Principal Investigator: Blanca Requejo Mañana, MD, Hospital Central de Asturias
- Principal Investigator: Ana Pando Sandoval, MD, Hospital Central de Asturias
- Principal Investigator: Carlos Martínez Rivera, MD, Germans Trias i Pujol Hospital
- Principal Investigator: Xavier Muñoz Gall, MD, Hospital Vall d'Hebrón
- Principal Investigator: Gaspar Dalmau Duch, MD, Hospital Joan XXIII
- Principal Investigator: Luis Alejandro Pérez de Llano, MD, Hospital Lucus Augusti
- Principal Investigator: Abel Pallarés Sanmartín, MD, Complejo Hospitalario Universitario de Vigo
- Principal Investigator: Vanesa García Paz, MD, Complejo Hospitalario Universitario de Santiago de Compostela
- Principal Investigator: Francisco Javier Callejas González, MD, Hospital del Perpetuo Socorro de Albacete
- Principal Investigator: Patricia Prieto Montaño, MD, Hospital del Perpetuo Socorro de Albacete
- Principal Investigator: Ana Tabar Purroy, MD, Complejo Hospitalario de Navarra
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EffICIENCY